CHANGES IN ULTRASTRUCTURE OF HEPATOCYTES AND LIVER TEST-RESULTS BEFORE, DURING, AND AFTER TREATMENT WITH INTERFERON-BETA IN PATIENTS WITH HBEAG-POSITIVE CHRONIC ACTIVE HEPATITIS

被引:6
|
作者
ITOH, S
MARUTANI, K
MATSUO, S
机构
[1] Third Department of Medicine, Saitama Medical School, Saitama
关键词
HEPATITIS-B E-ANTIGEN-POSITIVE CHRONIC ACTIVE HEPATITIS; INTERFERON-BETA; ENDOPLASMIC RETICULUM; GLYCOGEN PARTICLES; ALANINE AMINOTRANSFERASE; ALBUMIN;
D O I
10.1007/BF01296570
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
We studied the histological and ultrastructural changes in the liver and alterations in the fiver test results before, during, and after treatment with human interferon-beta from five patients with hepatitis B e antigen-positive chronic active hepatitis. A daily dose of 3 X 10(6) to 6 X 10(6) units of interferon-beta was given intravenously for four weeks. The total index of periportal and portal inflammation, intralobular degeneration, and focal necrosis before treatment was decreased significantly six months after treatment (P < 0.05). Ultrastructurally, the structure of endoplasmic reticulum was irregularly shaped or fragmentally decreased during treatment, but these disappeared six or 12 months after treatment. Glycogen particles diminished greatly during treatment. The alanine aminotransferase concentrations in these patients increased during treatment. Serum albumin and cholinesterase levels decreased significantly al the fourth week of treatment (P < 0.01) and at the third day (P < 0.01) to the second week (P < 0.05) of treatment, respectively. These results suggest that interferon-beta injures endoplasmic reticulum and glycogen areas and damages the cholinesterase activity in the early stage of treatment and protein synthesis in patients with hepatitis B e antigen-positive chronic active hepatitis.
引用
收藏
页码:1260 / 1267
页数:8
相关论文
共 50 条
  • [41] The Predictive Value of Baseline HBsAg Level and Early Response for HBsAg Loss in Patients with HBeAg-positive Chronic Hepatitis B during Pegylated Interferon Alpha-2a Treatment
    LI Ming Hui
    ZHANG Lu
    QU Xiao Jing
    LU Yao
    SHEN Ge
    LI Zhen Zhen
    WU Shu Ling
    LIU Ru Yu
    CHANG Min
    HU Lei Ping
    HUA Wen Hao
    SONG Shu Jing
    WAN Gang
    XIE Yao
    Biomedical and Environmental Sciences, 2017, 30 (03) : 177 - 184
  • [42] The Predictive Value of Baseline HBsAg Level and Early Response for HBsAg Loss in Patients with HBeAg-positive Chronic Hepatitis B during Pegylated Interferon Alpha-2a Treatment
    Li Ming Hui
    Zhang Lu
    Qu Xiao Jing
    Lu Yao
    Shen Ge
    Li Then Zhen
    Wu Shu Ling
    Liu Ru Yu
    Chang Min
    Hu Lei Ping
    Hua Wen Hao
    Song Shu Jing
    Wan Gang
    Xie Yao
    BIOMEDICAL AND ENVIRONMENTAL SCIENCES, 2017, 30 (03) : 177 - 184
  • [43] Reply: Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of Patients with HBeAg-Positive
    Choi, Won-Mook
    Lim, Young-Suk
    HEPATOLOGY, 2024, 80 (02) : E28 - E28
  • [44] HEPATITIS-C RNA IN LIVER OF CHRONIC HEPATITIS-C PATIENTS BEFORE AND AFTER INTERFERON ALFA TREATMENT
    BALART, LA
    PERRILLO, R
    RODDENBERRY, J
    REGENSTEIN, F
    SHIM, KS
    SHIEH, SC
    TAYLOR, B
    DASH, S
    GERBER, MA
    GASTROENTEROLOGY, 1993, 104 (05) : 1472 - 1477
  • [45] Dynamic Changes of Cytokine Profiles and Virological Markers Associated With HBsAg Loss During Peginterferon Alpha-2a Treatment in HBeAg-Positive Chronic Hepatitis B Patients
    Li, Minghui
    Zhang, Luxue
    Xie, Si
    Sun, Fangfang
    Zeng, Zhan
    Deng, Wen
    Jiang, Tingting
    Bi, Xiaoyue
    Lin, Yanjie
    Yang, Liu
    Lu, Yao
    Shen, Ge
    Liu, Ruyu
    Wu, Shuling
    Chang, Min
    Hu, Leiping
    Dong, Jianping
    Yi, Wei
    Xie, Yao
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [46] HBV DNA IN THE LIVER OF PATIENTS WITH CHRONIC ACTIVE HEPATITIS-B BEFORE AND AFTER TREATMENT WITH ALPHA-INTERFERON (WELLFERON, WELLCOME)
    FEINMAN, SV
    BERRIS, B
    FERNANDES, B
    SOOKNANAN, R
    HEPATOLOGY, 1988, 8 (05) : 1222 - 1222
  • [47] DIFFERENT KINETICS OF SERUM HBSAG DECLINE IN HBEAG-POSITIVE VS HBEAG-NEGATIVE PATIENTS DURING 3 YEARS OF TELBIVUDINE TREATMENT IN CHRONIC HEPATITIS B (CHB)
    Wursthorn, Karsten
    Jung, Mechthild
    Manns, Michael P.
    Lopez, Patricia M.
    Wedemeyer, Heiner
    Naoumov, Nikolai V.
    HEPATOLOGY, 2009, 50 (04) : 536A - 536A
  • [48] Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response
    ter Borg, Martijn J.
    van Zonneveld, Monika
    Zeuzem, Stefan
    Senturk, Hakan
    Akarca, Ulus S.
    Simon, Christopher
    Hansen, Bettina E.
    Haagmans, Bart L.
    de Man, Robert A.
    Schalm, Solko W.
    Janssen, Harry L. A.
    HEPATOLOGY, 2006, 44 (03) : 721 - 727
  • [49] Reduced liver-related complications after 13 years of follow-up of interferon-alpha treatment for HBeAg-positive chronic hepatitis B: The ELITE-B study
    Choi, Hannah S. J.
    van Campenhout, Margo J. H.
    de Jong, Cedric
    van Vuuren, Hanneke
    Sonneveld, Milan
    de Knegt, Robert
    Hansen, Bettina
    Janssen, Harry
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E460 - E460
  • [50] ASSESSMENT OF LIVER-FUNCTION BEFORE, DURING AND AFTER INTERFERON (IFN) TREATMENT FOR CHRONIC HEPATITIS-C
    LIRUSSI, F
    CROVATTO, M
    SANTINI, G
    BECCARELLO, A
    BORTOLATO, L
    TRICHES, C
    PALEARI, C
    OKOLICSANYI, L
    CREPALDI, G
    HEPATOLOGY, 1995, 22 (04) : 1367 - 1367